Passer au contenu principal
Mandats représentatifs

Kardium Inc. Completes US$115M Series D Financing Round Led by Fidelity and T.Rowe Price

Fasken
Temps de lecture 2 minutes
Partager

Aperçu

Mandat

Kardium Inc.

On January 25, 2021, Vancouver-based Kardium Inc., announced that they had raised US $115 million in a new financing round led by Fidelity Management & Research Company LLC., together with other follow-on participation funds and accounts advised by T. Rowe Price Associates, Inc.

Kardium announced that the new financing will be used to accelerate commercial growth of their Globe® Mapping and Ablation System in order to offer innovative atrial fibrillation treatment for millions of patients worldwide. The investment allows the company to accelerate commercial sales in Europe, as well as to begin the FDA clinical study for the Globe System.

Fasken advised Kardium Inc. with a team led by Shahrooz Nabavi (Corporate/Commercial and Corporate Finance) and included Iain Mant (Securities), Mike Coburn (Tax), Geoff Pedlow, Katie Peardon and Rasmeet Mohar (Corporate/Commercial and Corporate Finance). 

Juridiction

  • Colombie-Britannique

Équipe

  • Shahrooz Nabavi, Associé, Vancouver, BC, +1 604 631 4910, snabavi@fasken.com
  • Iain Mant, Associé, Vancouver, BC, +1 604 631 4734, imant@fasken.com
  • Michael Coburn, Associé, Vancouver, BC, +1 604 631 4832, mcoburn@fasken.com
  • Geoff Pedlow, Associé, Vancouver, BC, +1 604 631 4765, gpedlow@fasken.com
  • Katie Chandler, Associée, Vancouver, BC, +1 604 631 4860, kchandler@fasken.com
  • Rasmeet Mohar, Avocate, Vancouver, BC, +1 604 631 3218, rmohar@fasken.com